Ruxolitinib, a potent JAK1/2 inhibitor, is approved for patients with PV who are resistant, intolerant, or experience significant adverse effects from conventional cytoreductive therapies such as hydroxyurea [3]. Here, JAK1 is linked to acquired polycythemia vera.